tbuckley/cabot-search huggingface dataset:
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Authors: Vera A. Bittner, Michael Szarek, Philip E. Aylward, Deepak L. Bhatt, Rafael Diaz, Jay M. Edelberg, Zlatko Fras, Shaun G. Goodman, Sigrun Halvorsen, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Virginie Loizeau, Patrick M. Moriarty, Angèle Moryusef, Robert Pordy, Matthew T. Roe, Peter Sinnaeve, Sotirios Tsimikas, Robert Vogel, Harvey D. White, Doron Zahger, Andreas M. Zeiher, Ph. Gabriel Steg, Gregory G. Schwartz
Journal: Journal of the American College of Cardiology (2020)

Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C independently predicted major adverse cardiovascular events (MACE).One to 12 months after ACS, 18,924 patients on high-intensity statin therapy were randomized to alirocumab or placebo and followed for 2.8 years (median). Lipoprotein(a) was measured at randomization and 4 and 12 months thereafter. The primary MACE outcome was coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina.Baseline lipoprotein(a) levels (median: 21.2 mg/dl; interquartile range [IQR]: 6.7 to 59.6 mg/dl) and LDL-C [corrected for cholesterol content in lipoprotein(a)] predicted MACE. Alirocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 to 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.78 to 0.93). Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics. A 1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.990 to 0.999; p = 0.0081).Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS. Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Authors: Everett J. Moding, Yufei Liu, Barzin Y. Nabet, Jacob J. Chabon, Aadel A. Chaudhuri, Angela B. Hui, Rene F. Bonilla, Ryan B. Ko, Christopher H. Yoo, Linda Gojenola, Carol D. Jones, Jianzhong He, Yawei Qiao, Ting Xu, John V. Heymach, Anne Tsao, Zhongxing Liao, Daniel R. Gomez, Millie Das, Sukhmani K. Padda, Kavitha J. Ramchandran, Joel W. Neal, Heather A. Wakelee, Billy W. Loo, Steven H. Lin, Ash A. Alizadeh, Maximilian Diehn
Journal: Nature Cancer (2020)

Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple tumor types, but whether further treatment can improve outcomes in patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 patients receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 patients receiving consolidation immune checkpoint inhibition (CICI). Patients with undetectable ctDNA after CRT had excellent outcomes whether or not they received CICI. Among such patients, one died from CICI-related pneumonitis, highlighting the potential utility of only treating patients with MRD. In contrast, patients with MRD after CRT who received CICI had significantly better outcomes than patients who did not receive CICI. Furthermore, the ctDNA response pattern early during CICI identified patients responding to consolidation therapy. Our results suggest that CICI improves outcomes for NSCLC patients with MRD and that ctDNA analysis may facilitate personalization of consolidation therapy.
Effects of spaceflight on the composition and function of the human gut microbiota
Authors: Zizhong Liu, Gui Luo, Ruikai Du, Weijia Sun, Jianwei Li, Haiyun Lan, Pu Chen, Xinxin Yuan, Dengchao Cao, Yuheng Li, Caizhi Liu, Shuai Liang, Xiaoyan Jin, Ruifu Yang, Yujing Bi, Yanping Han, Ping Cao, Wei Zhao, Shukuan Ling, Yingxian Li
Journal: Gut Microbes (2020)

Interaction between humans and the gut microbiota is important for human physiology. Here, the gut microbiota was analyzed via metagenomic sequencing, and the fluctuations in the gut microbiota under the conditions of spaceflight were characterized. The composition and function of the gut microbiota were substantially affected by spaceflight; however, individual specificity was uncompromised. We further confirmed the species fluctuations and functional genes from both missions. Resistance and virulence genes in the gut microbiota were affected by spaceflight, but the species attributions remained stable. Spaceflight markedly affected the composition and function of the human gut microbiota, implying that the human gut microbiota is sensitive to spaceflight.
Cervical cancer treatment for operable lesions in a low-resource contemporary setting.
Authors: Caroline Dorothy Lynch, Elkanah Omenge, Peter Itsura, Hellen Muliro, Guiseppe DelPriore, Barry Rosen, Sierra Washington, Robert Matthew Strother
Journal: Journal of Clinical Oncology (2012)

5107 Background: To compare HIV+ and HIV- women with operable cervical cancer in a low resource contemporary setting. Methods: A retrospective study using well-matched controls from a Kenyan teaching and referral hospital. Results: 183 women were treated for cervical cancer between October 2007 and June 2011. The histologic subtype was squamous cell in all but one case. At presentation, 28 had operable lesions (Stage IA1–IIB1); 7 more received neoadjuvant chemotherapy prior to surgery. HIV seroprevalence was 54% (18/33) among initial operative cases and 57% among the neoadjuvant group (p=ns). Mean age was 42 (HIV+), and 43 (HIV-), (range 25-64). HIV- vs. HIV+ cervical cancer patients (mean CD4 count 373, 50%&lt;200) were detected by visual inspection with acetic acid (VIA) (18% (2/11)vs 68% (15/22) p=.099), symptoms (27%(3/11) vs 14%(3/22) p=.43), or Pap smear (45% (5/11) vs .09% (2/22) p=.06), respectively.HIV+ patients (two Stage IB1, two Stage IB2) did not require more downstaging than HIV- patients (two stage IIB, one stage IIIA) before surgery (18% (4/22) vs 27% (3/11) p=.63). Surgical treatments were not statistically different in either group and included radical hysterectomy(25), total abdominal hysterectomy(2), cesarean hysterectomy(1), and total vaginal hysterectomy(5). Postoperative complications included fever, dehiscence, DVT, ileus, fistula, and infectious complications (chest, urinary tract, wound). One HIV- patient suffered postoperative fever, vesicovaginal fistula, and wound dehiscence (overall complications .06%).Lymph node involvement was noted in 7 HIV+ and 3 HIV- patients who underwent full staging procedures (p=.004). Conclusions: In patients with operable cervical cancer, HIV serostatus does not affect complication rate or influence need for downstaging prior to surgery compared to a well-matched control group. HIV+ patients were not more likely to receive neoadjuvant chemotherapy but were more likely to have positive lymph nodes. VIA detected the majority of cervical cancers HIV+ patients.
Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) (BIBW 2992) in Combination with Gemcitabine (G) in Patients (PTS) with Advanced Solid Tumours
Authors: S. Zanetta, J. Bennouna, N. Isambert, H. De Mont-Serrat, I. Tschoepe, P. Squiban, J. Delord
Journal: Annals of Oncology (2012)
Abstract 282: Cerebral Oximetry to Identify Return of Spontaneous Circulation in Patients Treated With Manual or Mechanical Chest Compressions
Authors: Ruth Salaberria, Andima Larrea, Leyre Amas, Felix Zubia, Miren Begoña Zubero, Daniel Alonso, Unai Irusta, Elisabete Aramendi
Journal: Circulation (2019)

Background: Near infrared spectroscopy can be used to monitor cerebral oxygen saturation in out-of-hospital cardiac arrest (OHCA). Brain oxygen saturation increase has been associated to cardiopulmonary resuscitation therapy (CPR), and higher saturation values are observed during return of spontaneous circulation (ROSC) and in survivors. In this study we evaluate cerebral oxygen saturation to identify ROSC, and compare its value for patients treated with manual or mechanical CPR. Materials and Methods: A total of 87 OHCA patients treated by the Emergency medical system (EMS) of the Basque Country were included, 32 treated with manual CPR and 55 with the LUCAS-3 device (Stryker). Brain oxygen saturation was measured in the left and right lobes using the NIRO NX-200 (Hamamatsu) in the manual group, and the SenSmart X-100 (NONIN) in the LUCAS-3 group. For each patient the mean value of the left and right lobe saturation in the first minute after the end of chest compressions was computed. Saturation values for the ROSC/no-ROSC groups were compared using the Wilcoxon rank sum test, p&lt;0.01 was considered significant. The area under the curve (AUC) was computed for each CPR group to measure how well brain saturation discriminates ROSC from no-ROSC. Results: In the manual CPR group median (IQR) saturation values were 39.2% (33.6-49.7) for the no-ROSC (n=23) and 64.3% (55.2-67.0) for ROSC (n=9) (p&lt;0.01), and the AUC was 0.92. In the LUCAS-3 CPR group saturation values were 41.5% (29.8-50.5) for the no-ROSC (n=37) and 67.0% (61.8-75.0) for ROSC (n=18) (p&lt;0.01), and the AUC was 0.91. No significant differences in saturation were observed between manual and mechanical CPR for both ROSC (p=0.46) and no-ROSC patients (p=0.28). Conclusions: Differences in cerebral oximetry were significant between ROSC and no-ROSC patients. No differences were observed in saturation between the manual and mechanical CPR groups, despite using different oximeter models. Cerebral oximetry could be used to predict outcome regardless of the type of CPR.
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Authors: Edouard J. Trabulsi, R. Bryan Rumble, Hossein Jadvar, Thomas Hope, Martin Pomper, Baris Turkbey, Andrew B. Rosenkrantz, Sadhna Verma, Daniel J. Margolis, Adam Froemming, Aytekin Oto, Andrei Purysko, Matthew I. Milowsky, Heinz-Peter Schlemmer, Matthias Eiber, Michael J. Morris, Peter L. Choyke, Anwar Padhani, Jorge Oldan, Stefano Fanti, Suneil Jain, Peter A. Pinto, Kirk A. Keegan, Christopher R. Porter, Jonathan A. Coleman, Glenn S. Bauman, Ashesh B. Jani, Jeffrey M. Kamradt, Westley Sholes, H. Alberto Vargas
Journal: Journal of Clinical Oncology (2020)

Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups.An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality.A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles.One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.
Feasibility Study of High Dose Cisplatin Administered with Short Hydration and Magnesium Supplementation in Patients with Lung Cancer
Authors: H. Horinouchi, K. Kubota, H. Itani, H. Wakui, S. Nakamichi, S. Kanda, H. Nokihara, N. Yamamoto, I. Sekine, T. Tamura
Journal: Annals of Oncology (2012)
Induction Chemotherapy (CT) with Docetaxel, Cisplatin, and Fluorouracil (TPF) Followed by Concomitant Cisplatin Plus Radiotherapy in Locally Advanced Nasopharyngeal Cancer (NPC) Results after 03 Years
Authors: E. Kerboua, N. Lagha, A. Arab, S. Chami, F. Mekki, K. Bouzid
Journal: Annals of Oncology (2012)
Global prevalence of hepatitis C virus in children in 2018: a modelling study
Authors: Jonathan Schmelzer, Ellen Dugan, Sarah Blach, Samantha Coleman, Zongzhen Cai, Mindi DePaola, Chris Estes, Ivane Gamkrelidze, Kathryn Jerabek, Siyi Ma, Shauna Montoya, Devin Razavi-Shearer, Kathryn Razavi-Shearer, Sarah Robbins-Scott, Homie Razavi, Manal Hamdy El Sayed
Journal: The Lancet. Gastroenterology & hepatology (2020)
P-0085 Locally Advanced/Metastatic Cholangiocarcinoma Treated with Stent, Gemcitabine/Capecitabine Plus-Minus Photodynamic Therapy (Temoporfin) – Preliminary Results From a Norwegian Phase II Trial
Authors: Petra Weber Hauge, Truls Hauge, Trond Warloe, Isabel Franco-Lie, Anders Drolsum, Catrine Johansen, Ellen Viktil, Lars Aabakken, Trond Buanes, Zbigniew Konopski
Journal: Annals of Oncology (2012)
Is Adjuvant Chemoradiotherapy Necessary for High-Risk Oropharyngeal Cancer after Surgery?
Authors: T. Yokota, T. Onitsuka, K. Kusafuka, H. Ogawa, Y. Onozawa, M. Nakagawa, Y. Iida, T. Kamijo, N. Hirasawa, T. Nishimura, T. Nakajima, N. Boku, H. Yasui
Journal: Annals of Oncology (2012)
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
Authors: Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro, Yanhua Wang, Olga Derman, Randin Nelson, Joan Uehlinger, Kira Gritsman, R. Alejandro Sica, Noah Kornblum, Ioannis Mantzaris, Aditi Shastri, Murali Janakiram, Mendel Goldfinger, Amit Verma, Ira Braunschweig, Lizamarie Bachier-Rodriguez
Journal: Journal of Hematology & Oncology (2020)

Abstract Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.
Higher habitual flavonoid intake is associated with lower atherosclerotic cardiovascular disease hospitalizations
Authors: Frederik Dalgaard, Nicola P. Bondonno, Kevin Murray, Catherine P. Bondonno, Joshua R. Lewis, Kevin D. Croft, Cecilie Kyrø, Gunnar Gislason, Augustin Scalbert, Aedin Cassidy, Anne Tjønneland, Kim Overvad, Jonathan M. Hodgson
Journal: The Lancet Planetary Health (2019)
Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug–metabolite atlas
Authors: Jun Liu, Lies Lahousse, Michel G. Nivard, Mariska Bot, Lianmin Chen, Jan Bert van Klinken, Carisha S. Thesing, Marian Beekman, Erik Ben van den Akker, Roderick C. Slieker, Eveline Waterham, Carla J. H. van der Kallen, Irene de Boer, Ruifang Li-Gao, Dina Vojinovic, Najaf Amin, Djawad Radjabzadeh, Robert Kraaij, Louise J. M. Alferink, Sarwa Darwish Murad, André G. Uitterlinden, Gonneke Willemsen, Rene Pool, Yuri Milaneschi, Diana van Heemst, H. Eka D. Suchiman, Femke Rutters, Petra J. M. Elders, Joline W. J. Beulens, Amber A. W. A. van der Heijden, Marleen M. J. van Greevenbroek, Ilja C. W. Arts, Gerrit L. J. Onderwater, Arn M. J. M. van den Maagdenberg, Dennis O. Mook-Kanamori, Thomas Hankemeier, Gisela M. Terwindt, Coen D. A. Stehouwer, Johanna M. Geleijnse, Leen M. ‘t Hart, P. Eline Slagboom, Ko Willems van Dijk, Alexandra Zhernakova, Jingyuan Fu, Brenda W. J. H. Penninx, Dorret I. Boomsma, Ayşe Demirkan, Bruno H. C. Stricker, Cornelia M. van Duijn
Journal: Nature Medicine (2020)
Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial
Authors: Anders Granholm, Søren Marker, Mette Krag, Fernando G. Zampieri, Hans-Christian Thorsen-Meyer, Benjamin Skov Kaas-Hansen, Iwan C. C. van der Horst, Theis Lange, Jørn Wetterslev, Anders Perner, Morten Hylander Møller
Journal: Intensive Care Medicine (2020)
The Clinical Utility of a Change in the Royal Marsden Hospital Prognostic Score (RMHPS) in Patients (PTS) Prior to Phase I Clinical Trial Therapy
Authors: C.O. Michie, M. Ong, J. Mateo, A.M. Young, D. Olmos, J.E. Ang, L.R. Molife, U. Banerji, J.S. de Bono, S.B. Kaye
Journal: Annals of Oncology (2012)
Impact of Salvage Therapy with APC8015F on the Overall Survival (OS) Benefit Achieved with Sipuleucel-T in Three Phase 3 Studies of Metastatic Castrate-Resistant Prostate Cancer (MCRPC)
Authors: D.J. George, L.G. Gomella, T. Devries, J.B. Whitmore, M.W. Frohlich, C. Nabhan
Journal: Annals of Oncology (2012)
Patient reported outcomes for non-tuberculous mycobacterial disease
Authors: Michael R. Loebinger, Surinder S. Birring
Journal: European Respiratory Journal (2020)

<b>There is a pressing need for patient related outcome measures for pulmonary NTM disease, to assist with both clinical management decisions and as an endpoint for clinical studies. This NTM Module should be considered an important step in this development.</b>http://bit.ly/2OvmAQw
Efficacy and Safety of First-Line Platinum-Based Chemotherapy in Patients with Post-Operative Recurrence after Platinum-Based Adjuvant Chemotherapy
Authors: K. Muraki, H. Imai, T. Shukuya, R. Ohhashi, R. Koyama, T. Mori, H. Murakami, T. Takahashi, N. Yamamoto, K. Takahashi
Journal: Annals of Oncology (2012)
P-0194 A Friendly, Cheap and Very Sensitive Method for K-Ras Point Mutations Detection Based on PNA-Directed Pcr-Clamping in Metastatic Colorectal Carcinoma
Authors: Francesca Messa, Enrico Bracco, Enrico Millo, Federica Tonissi, Silvana Ungari, Laura Lattanzio, Marco Carlo Merlano, Gianluca Damonte, Cristiana Lo Nigro
Journal: Annals of Oncology (2012)
Biallelic CPAMD8 Variants Are a Frequent Cause of Childhood and Juvenile Open-Angle Glaucoma
Authors: Owen M. Siggs, Emmanuelle Souzeau, Deepa A. Taranath, Andrew Dubowsky, Angela Chappell, Tiger Zhou, Shari Javadiyan, Jillian Nicholl, Lisa S. Kearns, Sandra E. Staffieri, Andrew Narita, James E.H. Smith, John Pater, Alex W. Hewitt, Jonathan B. Ruddle, James E. Elder, David A. Mackey, Kathryn P. Burdon, Jamie E. Craig
Journal: Ophthalmology (2020)

Developmental abnormalities of the ocular anterior segment in some cases can lead to ocular hypertension and glaucoma. CPAMD8 is a gene of unknown function recently associated with ocular anterior segment dysgenesis, myopia, and ectopia lentis. We sought to assess the contribution of biallelic CPAMD8 variants to childhood and juvenile open-angle glaucoma.Retrospective, multicenter case series.A total of 268 probands and their relatives with a diagnosis of childhood or juvenile open-angle glaucoma.Developmental abnormalities of the ocular anterior segment in some cases can lead to ocular hypertension and glaucoma. CPAMD8 is a gene of unknown function recently associated with ocular anterior segment dysgenesis, myopia, and ectopia lentis. We sought to assess the contribution of biallelic CPAMD8 variants to childhood and juvenile open-angle glaucoma.Patients underwent a comprehensive ophthalmic assessment, with DNA from patients and their relatives subjected to genome, exome, or capillary sequencing. CPAMD8 RNA expression analysis was performed on tissues dissected from cadaveric human eyes.Diagnostic yield within a cohort of childhood and juvenile open-angle glaucoma, prevalence and risk of ophthalmic phenotypes, and relative expression of CPAMD8 in the human eye.We identified rare (allele frequency < 4×10-5) biallelic CPAMD8 variants in 5.7% (5/88) of probands with childhood glaucoma and 2.1% (2/96) of probands with juvenile open-angle glaucoma. When including family members, we identified 11 individuals with biallelic variants in CPAMD8 from 7 unrelated families. Nine of these individuals were diagnosed with glaucoma (9/11, 81.8%), with a mean age at diagnosis of 9.22±14.89 years, and all individuals with glaucoma required 1 or more incisional procedures to control high intraocular pressure. Iris abnormalities were observed in 9 of 11 individuals, cataract was observed in 8 of 11 individuals (72.7%), and retinal detachment was observed in 3 of 11 individuals (27.3%). CPAMD8 expression was highest in neural crest-derived tissues of the adult anterior segment, suggesting that CPAMD8 variation may cause malformation or obstruction of key drainage structures.Biallelic CPAMD8 variation was associated with a highly heterogeneous phenotype and in our cohorts was the second most common inherited cause of childhood glaucoma after CYP1B1 and juvenile open-angle glaucoma after MYOC. CPAMD8 sequencing should be considered in the investigation of both childhood and juvenile open-angle glaucoma, particularly when associated with iris abnormalities, cataract, or retinal detachment.